The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Profitability metrics showed a sharper upward trend. Gross margin expanded 280 basis points to 61.2%
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients
Good momentum in commercial CDMO business
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239
The company allocated €56 million to research and development for next-generation line solutions
The company reported net revenue of SEK 13.5 million for the full year 2025
Subscribe To Our Newsletter & Stay Updated
